Trial Profile
A Phase 2a, Single-center Study Investigating the Short-term Renal Hemodynamic Effects, Safety and Pharmacokinetics/ Pharmacodynamics of Oral Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease at Various Stages of Renal Function
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Jul 2017
Price :
$35
*
At a glance
- Drugs Tolvaptan (Primary)
- Indications Autosomal dominant polycystic kidney disease
- Focus Pharmacodynamics
- Sponsors Otsuka Pharmaceutical Development & Commercialization
- 23 Apr 2014 New trial record